Europe s Affitech, Axaron Form Alliance to Develop Antibodies | GenomeWeb

NEW YORK, Dec. 4 – Affitech of Oslo and Axaron Bioscience of Heidelberg, Germany, said Tuesday that they had agreed to jointly develop and sel antibody drugs for neurological disorders. 

Axaron, formerly known as BASF-Lynx Bioscience, will use its transcription profiling technologies to identify targets that Affitech will then use in the development of antibodies. Both companies will support the effort to bring the antibodies through preclinical and clinical trials.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.